MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Aandelen Lijst・Pulse Biosciences Inc

Pulse Biosciences Inc

Gesloten

SectorGezondheidszorg

14.4 -1.84

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.35

Max

15.02

Belangrijke statistieken
By Trading Economics
Inkomsten	-217K -19M
Verkoop	86K 86K
EPS	-0.29
Winstmarge	-22,540.698
Werknemers	75
EBITDA	-228K -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+49.46% upside

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-179M 958M
Vorige openingsprijs	16.24
Vorige sluitingsprijs	14.4

Nieuwssentiment

By Acuity

13%

87%

16 / 370 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

16.59 / 17.17 Steun & Weerstand

Pulse Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jan 2026, 22:18 UTC

Marktinformatie

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 jan 2026, 21:43 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 jan 2026, 20:39 UTC

Marktinformatie

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 jan 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 jan 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 jan 2026, 20:30 UTC

Marktinformatie

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 jan 2026, 20:15 UTC

Marktinformatie

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 jan 2026, 19:58 UTC

Acquisities, Fusies, Overnames

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 jan 2026, 19:42 UTC

Marktinformatie

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 jan 2026, 19:38 UTC

Acquisities, Fusies, Overnames

Wolters Kluwer Acquires StandardFusion >WTKWY

9 jan 2026, 19:31 UTC

Winsten

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 jan 2026, 19:28 UTC

Winsten

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 jan 2026, 18:30 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 jan 2026, 18:23 UTC

Marktinformatie

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 17:19 UTC

Marktinformatie

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jan 2026, 17:07 UTC

Marktinformatie

McDonald's Promotions Appear Successful -- Market Talk

9 jan 2026, 17:06 UTC

Marktinformatie

Oil Futures on Track for Weekly Gains -- Market Talk

9 jan 2026, 17:05 UTC

Winsten

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 jan 2026, 16:57 UTC

Marktinformatie

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Vergelijking

Prijswijziging

Pulse Biosciences Inc Prognose

Koersdoel

By TipRanks

49.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD 49.46%

Hoogste 22 USD

Laagste 22 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pulse Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Pulse Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

16.59 / 17.17Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

16 / 370 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.